YIYukio Iwashita

Yukio Iwashita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yukio Iwashita has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Atsushi Sasaki

    Department of Surgery I, Oita University Faculty of Medicine, Hasama‐machi, Oita 879‐5593

    2 shared publications
  • Masayuki Ohta

    Department of Surgery I, Oita University Faculty of Medicine, Hasama‐machi, Oita 879‐5593

    2 shared publications
  • Seigo Kitano

    Department of Surgery I, Oita University Faculty of Medicine, Hasama‐machi, Oita 879‐5593

    2 shared publications
  • Jian Dou

    Department of Surgery I, Faculty of Medicine, Oita University, Oita 879-5593, Japan

    1 shared publication
  • Masafumi Inomata

    Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Idaigaoka 1-1, Hasama-machi, Yufu City, Oita, Japan

    1 shared publication
  • Masayuki Tominaga

    Department of Surgery I, Oita University Faculty of Medicine, Hasama‐machi, Oita 879‐5593

    1 shared publication

Latest Publications

  • Laparoscopic narrowband imaging for intraoperative diagnosis of the depth of invasion of gallbladder carcinoma: a preliminary study

    by Yukio Iwashita, Masafumi Inomata

    Determining the depth of invasion before surgery is one of the most important unsolved issues in the management of gallbladder cancer (GBC). We hypothesized that the assessment of irregular vessels on the gallbladder wall with use of narrow band imaging (NBI) may be useful for detecting subserosal infiltration. We present an initial report on the clinical usefulness of laparoscopic NBI for the intraoperative diagnosis of the depth of invasion in GBC.


  • Open Access

    Dendritic cell immunotherapy with poly(d,l‐2,4‐diaminobutyric acid)‐mediated intratumoral delivery of the interleukin‐12 gene suppresses tumor growth significantly

    by Yukio Iwashita, Shigeru Goto, Masayuki Tominaga, Atsushi Sasaki, Naoya Ohmori, Takeshi Goto, Syuji Sato, Masayuki Ohta, Seigo Kitano

    A conventional DC‐based immunotherapy has been tested clinically for treatment of patients with advanced cancer but requires modification to further improve the clinical results. In this study, we evaluated the in vivo antitumor effects of DC therapy, non‐viral‐mediated IL‐12 gene therapy, and a combination of the two in a murine bilateral subcutaneous tumor model. DC therapy alone and IL‐12 gene therapy alone suppressed tumor growth at the injected sites. However, the antitumor effect on the distant contralateral tumor was insufficient. When DC therapy and IL‐12 gene therapy were carried out simultaneously, tumor growth was significantly suppressed bilaterally (P < 0.001). Cytolytic activity was augmented significantly in mice given the combination treatment compared to in mice treated with either DC or IL‐12 gene therapy alone (P < 0.05). Microvessel density of both tumors was significantly lower in mice subjected to the combination therapy than in mice treated otherwise (P < 0.05). Furthermore, no side‐effects were observed in the treated mice. DC therapy combined with non‐viral‐mediated intratumoral IL‐12 gene delivery has a synergistic antitumor effect not only on targeted tumors but also on contralateral distant tumors and may be of great potential as a therapeutic treatment for patients with advanced cancer. (Cancer Sci 2005; 96: 303 –308)


  • Consensus interferon enhances the anti‐proliferative effect of 5‐fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression

    by Jian Dou, Yukio Iwashita, Atsushi Sasaki, Seiichiro Kai, Seitaro Hirano, Masayuki Ohta, Seigo Kitano

    Abstract: Background/Aims: The effectiveness of 5‐fluorouracil (5‐FU) treatment is influenced by the activities of pyrimidine catabolic enzymes. The aim of this study was to investigate whether interferon (IFN)‐α influences expression of 5‐FU catabolic or target‐related enzymes in human hepatoma cells.Methods: HepG2 cells were treated with 0, 0.15, 1.5, 15, and 150 ng/ml of consensus interferon (C‐IFN). Expression of mRNAs encoding dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase, and thymidylate synthase was examined by reverse transcription‐polymerase chain reaction before and after C‐IFN treatment. To determine the effect of pretreatment with C‐IFN on 5‐FU+C‐IFN combination therapy, we performed WST‐1 cell proliferation assays.Results: A significant reduction in the level of DPD mRNA was observed when HepG2 cells were pretreated with C‐IFN (PPConclusions: C‐IFN likely improves the anti‐tumor effect of 5‐FU via downregulation of DPD enzyme in hepatoma cells. Pretreatment with C‐IFN may increase the anti‐cancer effect of 5‐FU+C‐IFN combination therapy.